Prospective Randomized Controlled Trial of Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )
Eligibility
Participation Requirements
Sex: All
Minimum Age: 14
Healthy Volunteers: f
View:
• diagnosed with hematological diseases.
• Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.
• New onset of severe acute GVHD within 100 days post-transplantation.
Locations
Other Locations
China
Department of Hematology, the Fifth Center of Chinese PLA General Hospital
RECRUITING
Beijing
Contact Information
Primary
Daihong Liu
daihongrm@163.com
01066937079
Time Frame
Start Date: 2025-06-30
Estimated Completion Date: 2027-12-30
Participants
Target number of participants: 54
Treatments
Experimental: Ruxolitinib Arm
Ruxolitinib(5mg/d) combined with Methylprednisolone(1mg/kg)
Active_comparator: Comparator arm
Methylprednisolone (2mg/kg)
Related Therapeutic Areas
Sponsors
Leads: Daihong Liu